Removing Confidential Data In Clinical Trial Reports Is ‘Like Stepping On Lego’

More Than 90% Of Proposed CCI Redactions Are Public Information

An expert in transparency explained what drug sponsors can do to support their compliance staff in identifying commercially confidential information in accordance with the clinical trial transparency initiatives of Health Canada and the European Medicines Agency.

Close up cropped view unrecognizable businesspeople do paperwork during meeting in office, bank worker explain contracts terms conditions to client, discuss credit application, financial deal concept
Identifying CCI requires close coordination between multiple teams • Source: Shutterstock

Awful. Horrendous. Really difficult. This is how a clinical trial transparency expert describes the task of identifying confidential business information in clinical reports made public under the transparency initiatives of Health Canada and the European Medicines Agency.

Both initiatives involve the proactive disclosure of clinical data that were used to support a marketing authorization application after a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet